Novartis Agrees to Acquire Avidity Biosciences for $12 Billion by Wallstreet Journal | October 27, 2025 4:04 am | US Markets The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
